August 17, 2022 View Now | Addressing the Gaps in Clinical Trial Readiness for FSHD Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common myopathies affecting anywhere between 1:8,000 to 1:20,000
August 16, 2022 Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD Autosomal dominant polycystic kidney disease (ADPKD) is a major genetic disorder affecting up to 12 million individuals worldwide
August 12, 2022 Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies C-Path’s Type 1 Diabetes Consortium (T1DC) is pleased to announce that “Consortium-based approach to receiving an EMA...
August 5, 2022 PRO Consortium Announces Publication of Open Access Article C-Path’s PRO Consortium announces that “Comparing patient global impression of severity and patient global impression of chang
July 26, 2022 PSTC 15-year Anniversary Webinar Series Join scientists from PSTC member companies, health authorities and other key opinion leaders during the PSTC 15-year Anniversary W
July 25, 2022 Diary for Irritable Bowel Syndrome Symptoms-Constipation Now Available for Licensing C-Path’s PRO Consortium is pleased to announce that the Diary for Irritable Bowel Syndrome Symptoms–Constipation (DIBSS–C) i
July 19, 2022 Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
July 15, 2022 eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Administering Complex Cognitive Tests Remotely in The Cognitively-Impair
July 14, 2022 C-Path’s Dr. Amanda Klein Promoted to Transplant Therapeutic Consortium Executive Director TUCSON, Ariz., July 14, 2022 — Critical Path Institute (C-Path) has named Amanda Klein, Pharm.D., as Executive Director for its
